Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

NCT07067385 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Gastrointestinal Tumors

Interventions

BIOLOGICAL: Neoantigen Personalized Cancer Vaccine

Sponsor

Ruijin Hospital

Collaborators

[object Object]
[object Object]